Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Dabrafenib + Trametinib |
| Indication/Tumor Type | anaplastic thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975). | 27697975 |
| BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Guideline | Actionable | Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for patients with advanced or metastatic thyroid gland anaplastic carcinoma harboring BRAF V600E (PMID: 31549998, PMID: 35491008; ESMO.org). | 31549998 detail... 35491008 |
| BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 61% (20/33; 3 complete responses, 17 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E, with 12-month duration of response rate of 50%, a median progression-free survival and overall survival of 6.7 and 14.5 months, respectively (PMID: 35026411; NCT02034110). | 35026411 detail... detail... detail... |
| BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Guideline | Actionable | Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines as neoadjuvant treatment for anaplastic thyroid carcinoma patients harboring BRAF V600E with tage IVa or IVb borderline resectable disease, and as a preferred systemic therapy for those with metastatic disease (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27697975) | Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. | Full reference... |
| NCCN.org | Full reference... | |
| ESMO Clinical Practice Guidelines | Full reference... | |
| Full reference... | ||
| Mekinist (trametinib) FDA Drug Label | Full reference... | |
| Tafinlar (dabrafenib) FDA Drug Label | Full reference... | |
| (35491008) | ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. | Full reference... |
| (31549998) | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. | Full reference... |
| (35026411) | Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. | Full reference... |